PHASE 1 RANDOMIZED STUDY OF THE STEADY-STATE (SS) EFFECTS OF BEMPEDOIC ACID (BA) ON THE SINGLE-DOSE PHARMACOKINETICS (PK) OF ORAL CONTRACEPTIVE (OC) TABLETS IN HEALTHY FEMALES.

被引：0
|
作者：
Emery, M. [1 ]
MacDougall, D. [1 ]
Amore, B. [1 ]
McGonigal, J. [1 ]
Hanselman, J. [1 ]
Sasiela, W. [1 ]
机构：
[1] Esper Therapeut, Ann Arbor, MI USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIII-002
引用
收藏
页码：S79 / S79
页数：1
相关论文
共 46 条
  • [1] A PHASE 1 DRUG-DRUG INTERACTION STUDY ASSESSING THE EFFECTS OF STEADY STATE (SS) PROBENECID (PB) ON SINGLE-DOSE BEMPEDOIC ACID (BA) PHARMACOKINETICS (PK) IN HEALTHY SUBJECTS.
    Emery, M.
    Hanselman, J.
    MacDougall, D.
    Amore, B.
    Sasiela, W.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S43 - S43
  • [2] Single-dose and steady-state pharmacokinetics and safety of telbivudine following oral administration in healthy Chinese subjects
    Hu, P.
    Jiang, J.
    Wang, H.
    Pietropaolo, K.
    Chao, G.
    Brown, N.
    Zhou, X.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A129 - A129
  • [3] Effects of Varying Degrees of Renal Impairment on the Pharmacokinetics of DuloxetineAnalysis of a Single-Dose Phase I Study and Pooled Steady-State Data from Phase II/III Trials
    Evelyn D. Lobo
    Michael Heathman
    Han-Yi Kuan
    Shobha Reddy
    Lisa O’Brien
    Celedon Gonzales
    Michael Skinner
    Mary Pat Knadler
    Clinical Pharmacokinetics, 2010, 49 : 311 - 321
  • [4] Effect of Steady-State Ambrisentan on the Pharmacokinetics of a Single Dose of the Oral Contraceptive Norethindrone (Norethisterone) 1 mg/Ethinylestradiol 35 μg in Healthy Subjects An Open-Label, Single-Sequence, Single-Centre Study
    Spence, Rebecca
    Mandagere, Arun
    Walker, Gennyne
    Dufton, Christopher
    Boinpally, Ramesh
    CLINICAL DRUG INVESTIGATION, 2010, 30 (05) : 313 - 324
  • [5] Effect of Steady-State Ambrisentan on the Pharmacokinetics of a Single Dose of the Oral Contraceptive Norethindrone (Norethisterone) 1 mg/Ethinylestradiol 35 μg in Healthy SubjectsAn Open-Label, Single-Sequence, Single-Centre Study
    Rebecca Spence
    Arun Mandagere
    Gennyne Walker
    Christopher Dufton
    Ramesh Boinpally
    Clinical Drug Investigation, 2010, 30 : 313 - 324
  • [6] Effects of Varying Degrees of Renal Impairment on the Pharmacokinetics of Duloxetine Analysis of a Single-Dose Phase I Study and Pooled Steady-State Data from Phase II/III Trials
    Lobo, Evelyn D.
    Heathman, Michael
    Kuan, Han-Yi
    Reddy, Shobha
    O'Brien, Lisa
    Gonzales, Celedon
    Skinner, Michael
    Knadler, Mary Pat
    CLINICAL PHARMACOKINETICS, 2010, 49 (05) : 311 - 321
  • [7] Phase 1, randomized, open-label, single-dose, crossover study to evaluate the bio-equivalence of four formulations of oral rivoceranib tablets in healthy subjects.
    Weyer, Janelle
    Meng, Xianzhang
    Finis, Lynda
    Strickland, Bill
    Park, CheolHee
    Jang, Seong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, CROSSOVER STUDY TO EVALUATE THE INTERACTION OF MULTIPLE-DOSE ODEVIXIBAT WITH THE PHARMACOKINETICS OF SINGLE-DOSE COMBINED ORAL CONTRACEPTIVE STEROIDS IN HEALTHY FEMALE PARTICIPANTS
    Mazuir, Florent
    Ordonez, Claudia
    Wallefors, Terese
    Zhu, Judy
    Lindstrom, Erik
    HEPATOLOGY, 2024, 80 : S1773 - S1774
  • [9] Food Effects on the Pharmacokinetics of Doxylamine Hydrogen Succinate 25 mg Film-Coated Tablets A Single-Dose, Randomized, Two-Period Crossover Study in Healthy Volunteers
    Videla, Sebastian
    Lahjou, Mounia
    Guibord, Pascal
    Xu, Zhengguo
    Tolra, Carles
    Encina, Gregorio
    Sicard, Eric
    Sans, Artur
    DRUGS IN R&D, 2012, 12 (04) : 217 - 225
  • [10] SINGLE AND MULTIPLE-DOSE IV AND ORAL PHARMACOKINETICS (PK) OF THE HEDGEHOG PATHWAY INHIBITOR GDC-0449 DURING A PHASE 1 STUDY IN HEALTHY FEMALE
    Graham, R. A.
    Hop, C. E.
    Lum, B. L.
    Colburn, D.
    Chang, I.
    Shin, Y.
    Malhi, V.
    Xie, M.
    Low, J. A.
    Dresser, M. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S78 - S78
12345